Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia

Acadia Pharma (ACAD) to stop pimavanserin trials after failure

March 12, 2024 12:52 PM EDT

Shares of Acadia Pharma (NASDAQ: ACAD) plunged Tuesday after the company reported after the close on Monday that its Phase 3 ADVANCE-2 trial did not meet its primary endpoint.

The company's stock price is down more than 15% at $20.48 per share following the news.

The Phase 3 ADVANCE-2 trial was... More

Mizuho Downgrades Acadia Pharmaceuticals (ACAD) to Neutral

March 12, 2024 4:51 AM EDT

Mizuho analyst Uy Ear downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Buy to Neutral with a price target of $25.00 (from $39.00).

The analyst comments "Given the failed ADVANCE-2 trial, we remove our sales forecast for Nuplazid in negative symptoms of schizophrenia (NSS). With NSS... More

Acadia Pharma (ACAD) to Resume Trading at 4:35 p.m., Study Did Not Meet Primary Endpoint

March 11, 2024 4:10 PM EDT

Acadia Pharma (NASDAQ: ACAD) to Resume Trading at 4:35 p.m., Study Did Not Meet Primary Endpoint

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of... More